← board
RAJAF
distress 4/10 · elevated risk$9.180%today0% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.1 yrs
Shares 1y
0%
Price & events
+0.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.0%
1M
+0.0%
3M
+0.0%
6M
+0.0%
1Y
+22850.0%
2Y
—
5Y
+22850.0%
All
Overview
- Market Cap
- $1.02B
- Enterprise Value
- $1.02B
- Volume
- 0
- 52 Week Range
- $9.18 – $9.18
- Total Shares
- 111.12M
- Float Shares
- 18.27M
- % Held by Insiders
- 83.56%
- % Held by Institutions
- 0.00%
- Beta
- -57.53
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 111,120,000 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.